

## New number of shares and votes in Q-linea AB (publ)

The number of shares and votes in Q-linea AB (publ) (the “Company”) has increased during May as a result of the exercise of warrants of series TO1. A total of 1,981,751,629 new shares in the Company were subscribed for upon exercise of the TO1 warrants.

As of May 30, 2025, the total number of shares in the Company amounts to 6,430,039,725 shares (previously 4,448,288,096 shares), with one vote each. All shares are common shares. The share capital amounts to SEK 64,300,397.25 (previously SEK 44,482,880.96). As of May 30, 2025, Q-linea AB holds 328,472 of its own shares.

### For more information, please contact:

Stuart Gander, President & CEO, Q-linea

[Stuart.Gander@qlinea.com](mailto:Stuart.Gander@qlinea.com)

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

[Christer.Samuelsson@qlinea.com](mailto:Christer.Samuelsson@qlinea.com)

+46 (0) 70-600 15 20

### About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit [www.qlinea.com](http://www.qlinea.com)

*This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-05-30 08:30 CEST.*

### Attachments

[New number of shares and votes in Q-linea AB \(publ\)](#)